EyePoint Pharmaceuticals (“EyePoint” or the “Company”) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary bioerodible DURASERT E™ technology for sustained intraocular drug delivery. EyePoint’s lead product candidate, EYP-1901, is an investigational treatment currently in Phase 2 clinical trials, delivering vorolanib for the treatment of wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and non-proliferative diabetic retinopathy (NPDR). The Company is also advancing EYP-2301 into pre-clinical development, delivering razuprotafib formulated in DURASERT E™ for the potential treatment of diabetic eye diseases.